{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:06:32Z","timestamp":1788581192121,"version":"build-2803163510"},"reference-count":39,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1170276"],"award-info":[{"award-number":["APP1170276"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Behavioural variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder often neuropathologically associated with the accumulation of abnormally hyperphosphorylated tau, for which there is currently no disease-modifying treatment. Previous work by our group has shown sodium selenate upregulates the activity of protein phosphatase 2 in the brain, increasing the rate of tau dephosphorylation. The objective of this study is to evaluate the efficacy and safety of sodium selenate as a disease-modifying treatment for bvFTD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>This will be a multisite, phase IIb, double-blind placebo-controlled trial of sodium selenate. One hundred and twenty participants will be enrolled across 4 Australian academic hospitals. Following screening eligible participants will be randomised (1:1) to sodium selenate (15\u2009mg three times a day) or placebo for 52 weeks. Participants will have regular safety and efficacy visits throughout the study period. The primary study outcome will be percentage brain volume change (PBVC) as measured on MRI over 52 weeks of treatment. This will be analysed with a general linear model (analysis of covariance (ANCOVA)) with the PBVC as an output, the treatment as an input and the baseline brain volume as covariate for adjustment purposes. Secondary outcomes include safety and tolerability measures, and efficacy measures; change in cerebrospinal fluid total-tau, Addenbrooke\u2019s Cognitive Examination-III and Cambridge Behavioural Inventory-Revised scores over the 52 weeks of treatment. These will also be analysed with ANCOVA where the corresponding baseline measure will be incorporated in the model. Additional exploratory outcomes will include other imaging, cognitive and biospecimen analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>The study was approved by the Human Research and Ethics Committee of the lead site as part of the Australian Multisite Ethics approval system. The results of the study will be presented at national and international conferences and published in peer-reviewed journals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>ACTRN12620000236998 .<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2020-040100","type":"journal-article","created":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T21:21:07Z","timestamp":1605561667000},"page":"e040100","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1182-0907","authenticated-orcid":false,"given":"Lucy","family":"Vivash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B","family":"Malpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid","family":"Churilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Walterfang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Brodtmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Piguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah M","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley I","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M","family":"Hovens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Kalincik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Darby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Velakoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence J","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,16]]},"reference":[{"key":"2020111613201354000_10.11.e040100.1","unstructured":"Kettle M . Module 1: what is frontotemporal dementia? In: Frontotemporal dementia toolkit, 2011: 1\u201324."},{"key":"2020111613201354000_10.11.e040100.2","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/WNL.0000000000002638","article-title":"Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes","volume":"86","author":"Coyle-Gilchrist","year":"2016","journal-title":"Neurology"},{"key":"2020111613201354000_10.11.e040100.3","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.11.1615"},{"key":"2020111613201354000_10.11.e040100.4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5694\/mja16.01458","article-title":"Diagnosing, monitoring and managing behavioural variant frontotemporal dementia","volume":"207","author":"Piguet","year":"2017","journal-title":"Med J Aust"},{"key":"2020111613201354000_10.11.e040100.5","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306948"},{"key":"2020111613201354000_10.11.e040100.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2009.01.003"},{"key":"2020111613201354000_10.11.e040100.7","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1046\/j.1471-4159.1995.65062804.x","article-title":"Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase","volume":"65","author":"Goedert","year":"1995","journal-title":"J Neurochem"},{"key":"2020111613201354000_10.11.e040100.8","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/1.1.103"},{"key":"2020111613201354000_10.11.e040100.9","doi-asserted-by":"publisher","DOI":"10.1126\/science.6474172"},{"key":"2020111613201354000_10.11.e040100.10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.8.5535"},{"key":"2020111613201354000_10.11.e040100.11","article-title":"Sodium selenate treatment mitigates reduction of bone volume following traumatic brain injury in rats","volume":"16","author":"Brady","year":"2016","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"2020111613201354000_10.11.e040100.12","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605798"},{"key":"2020111613201354000_10.11.e040100.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2010.04.020"},{"key":"2020111613201354000_10.11.e040100.14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","article-title":"Tau pathology in Alzheimer disease and other tauopathies","volume":"1739","author":"Iqbal","year":"2005","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"2020111613201354000_10.11.e040100.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2011.12.005"},{"key":"2020111613201354000_10.11.e040100.16","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww116"},{"key":"2020111613201354000_10.11.e040100.17","doi-asserted-by":"crossref","unstructured":"Malpas CB , Vivash L , Genc S , et al . A phase iIa randomized control trial of VEL015 (Sodium Selenate) in mild-moderate alzheimer\u2019s disease. J Alzheimer\u2019s Dis 2016:1\u201310.","DOI":"10.3233\/JAD-160544"},{"key":"2020111613201354000_10.11.e040100.18","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv053"},{"key":"2020111613201354000_10.11.e040100.19","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.neuropharm.2016.05.001","article-title":"Sodium selenate, a protein phosphatase 2A activator, mitigates hyperphosphorylated tau and improves repeated mild traumatic brain injury outcomes","volume":"108","author":"Tan","year":"2016","journal-title":"Neuropharmacology"},{"key":"2020111613201354000_10.11.e040100.20","doi-asserted-by":"publisher","DOI":"10.1126\/science.7058341"},{"key":"2020111613201354000_10.11.e040100.21","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-013-8601-9"},{"key":"2020111613201354000_10.11.e040100.22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009038107"},{"key":"2020111613201354000_10.11.e040100.23","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0662-z"},{"key":"2020111613201354000_10.11.e040100.24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr179"},{"key":"2020111613201354000_10.11.e040100.25","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.49.4.1096"},{"key":"2020111613201354000_10.11.e040100.26","doi-asserted-by":"publisher","DOI":"10.1097\/00004728-200105000-00022"},{"key":"2020111613201354000_10.11.e040100.27","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.2002.1040"},{"key":"2020111613201354000_10.11.e040100.28","doi-asserted-by":"publisher","DOI":"10.1159\/000351671"},{"key":"2020111613201354000_10.11.e040100.29","doi-asserted-by":"publisher","DOI":"10.1017\/S1355617713001094"},{"key":"2020111613201354000_10.11.e040100.30","unstructured":"Burgess PW , Shallice T . Hayling and Brixton tests. Pearson, 1997."},{"key":"2020111613201354000_10.11.e040100.31","unstructured":"Spreen O , Strauss E . A compendium of neuropsychological tests: administration, norms and commentary. 2nd ed. New York: Oxford University Press, 1998."},{"key":"2020111613201354000_10.11.e040100.32","unstructured":"Benton AL , Hamsher K . Multilingual aphasia examination: manaul of instruction. Iowa City: University of Iowa, 1976."},{"key":"2020111613201354000_10.11.e040100.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-6177(03)00039-8"},{"key":"2020111613201354000_10.11.e040100.34","doi-asserted-by":"crossref","unstructured":"Wechsler D . Wechsler adult intelligence scale (WAIS\u2013IV). Vol. 22. 4th edn. San Antonio, TX: NCS Pearson, 2008.","DOI":"10.1037\/t15169-000"},{"key":"2020111613201354000_10.11.e040100.35","doi-asserted-by":"publisher","DOI":"10.1159\/000346389"},{"key":"2020111613201354000_10.11.e040100.36","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-301849"},{"key":"2020111613201354000_10.11.e040100.37","doi-asserted-by":"publisher","DOI":"10.1590\/S1980-57642009DN20200005"},{"key":"2020111613201354000_10.11.e040100.38","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/20.6.649"},{"key":"2020111613201354000_10.11.e040100.39","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.10.1756"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-040100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T21:21:17Z","timestamp":1605561677000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-040100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,16]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bmjopen-2020-040100"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-040100","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}